Weight reduction for non-alcoholic fatty liver disease
Authors:
- 15 June 2011
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6,p. CD003619
Abstract
Non-alcoholic fatty liver disease (NAFLD) is becoming a wide spread liver disease. The present recommendations for treatment are not evidence-based. Some of them are various weight reduction measures with diet, exercise, drug, or surgical therapy. To assess the benefits and harms of intended weight reduction for patients with NAFLD. We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, PubMed, EMBASE, Science Citation Index Expanded, Chinese Biomedicine Database, and ClinicalTrials.gov until February 2011. We included randomised clinical trials evaluating weight reduction with different measures versus no intervention or placebo in NAFLD patients. We extracted data independently. We calculated the odds ratio (OR) for dichotomous data and calculated the mean difference (MD) for continuous data, both with 95% confidence intervals (CI). The review includes seven trials; five on aspects of lifestyle changes (eg, diet, physical exercise) and two on treatment with a weight reduction drug 'orlistat'. In total, 373 participants were enrolled, and the duration of the trials ranged from 1 month to 1 year. Only one trial on lifestyle programme was judged to be of low risk of bias. We could not perform meta-analyses for the main outcomes as they were either not reported or there were insufficient number of trials for each outcome to be meta-analysed. We could meta-analyse the available data for body weight and body mass index only. Adverse events were poorly reported. The sparse data and high risk of bias preclude us from drawing any definite conclusion on lifestyle programme or orlistat for treatment of NAFLD. Further randomised clinical trials with low risk of bias are needed to test the beneficial and harmful effects of weight reduction for NAFLD patients. The long-term prognosis of development of fibrosis, mortality, and quality of life should be studied.Keywords
This publication has 76 references indexed in Scilit:
- Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 DiabetesDiabetes Care, 2010
- Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized studyInternational Journal of Obesity, 2010
- The effects of aerobic exercise on metabolic risk, insulin sensitivity and intrahepatic lipid in healthy older people from the Hertfordshire Cohort Study: a randomised controlled trialDiabetologia, 2010
- Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic SteatohepatitisHepatology, 2009
- Aerobic Exercise Training Reduces Hepatic and Visceral Lipids in Obese Individuals Without Weight Loss†Hepatology, 2009
- Orlistat for overweight subjects with nonalcoholic steatohepatitisHepatology, 2009
- Effects of Therapeutic Lifestyle Program on Ultrasound-diagnosed Nonalcoholic Fatty Liver DiseaseJournal of the Chinese Medical Association, 2008
- Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese childrenWorld Journal of Gastroenterology, 2008
- A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2006
- A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patientsAlimentary Pharmacology & Therapeutics, 2004